Background: COVID-19 became an international pandemic in March of 2020, claiming the lives of millions of people worldwide. To combat this deadly virus, an unprecedented global effort led to the development of many new vaccines against COVID-19 within a year. ...
Background: The standard approach to treating pediatric community-acquired pneumonia (CAP) is a 10-day course of antibiotics. However, two high-quality randomized control trials challenged this standard within the last 12 months. The SAFER Trial and CAP-IT Trial found treatment for CAP in ...
Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...
Background: On December 23, 2021, the FDA granted molnupiravir emergency use authorization for the treatment of patients with Covid-19. Molnupiravir is a nucleoside analog that inhibits SARS-CoV-2 replication and triggers viral RNA mutagenesis. Until the release of oral antivirals, clinicians ...
Background: The optimal approach to risk stratifying patients for pulmonary embolism (PE) remains elusive. Multiple decision instruments are available with varying degrees of complexity and acceptance among emergency medicine clinicians (Wells, Geneva, PERC, YEARS, age-adjusted D-dimer). The 2018 ACEP clinical ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
